Chinese pharmaceutical company Huadong Medicine's (SHE:000963) unit, Huadong Medicine (Hangzhou), agreed to acquire the exclusive commercialization rights of Beijing ImmunoPharma Technology's CD19-targeted autologous CAR-T candidate product IM19 chimeric antigen receptor T cell injection, according to the company's filing on the Shenzhen Stock Exchange.
Huadong Medicine will receive an initial payment of 125 million yuan and registration and sales milestone payments of up to 950 million yuan.
The drug is undergoing clinical trials as a treatment for relapsed or refractory diffuse large B cell lymphoma, acute B cell lymphoblastic leukemia and mantle cell lymphoma, the Sunday filing noted.
Shares of the company rose more than 2% in recent trade.
Price (RMB): ¥29.76, Change: ¥+0.85, Percent Change: +2.94%
Comments